Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRON-PH
2025-522936-14-00Phase 4Authorised
- Sponsor
- Ziekenhuis Oost-Limburg
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in pulmonary hypertension (PH) and iron deficiency anemia (IDA) comparing Ferric carboxymaltose with Placebo (sodium chloride) (2 arms). Primary endpoint: Change in 6-minute walk distance from baseline to 24 weeks. Planned start Dec 2025; status: authorised.
02
Drugs
ferric carboxymaltose
03
Conditions
pulmonary hypertension (PH)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on 2025-522936-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522936-14-00.